Tech Company Financing Transactions
Immusoft Funding Round
On 1/31/2023, Immusoft landed $8 million in funding from California Institute for Regenerative Medicine.
Transaction Overview
Company Name
Announced On
1/31/2023
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Undisclosed
Investors
California Institute for Regenerative Medicine (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its engineered B cell clinical program. This funding will support a Phase I study to evaluate the safety and tolerability of ISP-001 (for delivery of alpha-L-iduronidase, or IDUA) in MPS I a rare, childhood genetic disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
454 N 34th St.
Seattle, WA 98103
USA
Seattle, WA 98103
USA
Phone
Website
Email Address
Overview
Immusoft's mission is to develop a breakthrough autologous cell therapy platform for treating a variety of human diseases through our proprietary Immune System Programming (ISP) technology. ISP technology can effectively re-program a patient's own cells to become miniature drug factories in the body.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Ainsworth
Chief Scientific Officer
Robert Hayes
VP - Bus. Development
Cam Gallagher
VP - Bus. Development
Scott McIvor
VP - Regulatory Affairs
Monika Swietlicka
Browse more venture capital transactions:
Prev: 1/31/2023: Titan Academy venture capital transaction
Next: 1/31/2023: Ballislife venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs